Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: 0.00

Third Harmonic Bio Inc. Working Capital Turnover Ratio is 0.00 for the Trailing 12 Months (TTM) ending March 31, 2024, a 0.00% change year over year. The working capital turnover ratio measures the efficiency of a company in utilizing its working capital to generate revenue. It is calculated by dividing the revenue by the working capital. This ratio indicates the number of times the company's working capital is converted into revenue during a specific period. A higher working capital turnover ratio suggests more efficient utilization of working capital in revenue generation.

Third Harmonic Bio Inc. Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00, a 0.00% change year over year.
Third Harmonic Bio Inc. Working Capital Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends